Results 81 to 90 of about 24,588 (279)

Changes in antigen-specific T cell number and function during oral desensitization in cow’s milk allergy enabled with omalizumab [PDF]

, 2013
Food allergy is a major public health problem for which there is no effective treatment. We examined the immunological changes that occurred in a group of children with significant cow’s milk allergy undergoing a novel and rapid high dose oral ...
Bedoret, Denis, DeKruyff, Rosemarie H., Hamilton, R, Hoyte, E G, Nadeau, K C, Schneider, Lynda C., Shaw, V, Singh, A K, Umetsu, Dale T.   +8 more
core   +1 more source

Basophil Activation Test as Biomarker of Severity and Threshold of Allergic Reactions to Cow's Milk During Oral Food Challenges

Allergy, EarlyView.
The threshold of reactivity during fresh milk challenges was 70% lower than that of baked milk challenges, reflecting the higher allergenicity of fresh milk. BAT was the only biomarker statistically significantly different between severity and threshold groups, for baked milk and fresh milk allergies, respectively.
Holly Boyd, Irene Bartha, Ru‐Xin Foong, Marta Krawiec, Andreina Marques‐Mejias, Hannah F. Marshall, Suzana Radulovic, Faye Harrison, Grammatiki Antoneria, Zainab Jama, Matthew Kwok, Ewa Pietraszewicz, Malak Eghleilib, Cristian Ricci, Tom Marrs, Gideon Lack, George Du Toit, Alexandra F. Santos   +17 more
wiley   +1 more source

Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study

Risk Management and Healthcare Policy, 2020
Giorgio Walter Canonica, 1 Giorgio Lorenzo Colombo, 2, 3 Paola Rogliani, 4 Pierachille Santus, 5 Claudia Pitotti, 6 Sergio Di Matteo, 3 Chiara Martinotti, 3 Giacomo Matteo Bruno 3 1Asthma & Allergy Clinic, Humanitas University, Milan, Italy; 2S.A.V.
Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo S, Martinotti C, Bruno GM   +7 more
doaj  

Precision Medicine in Targeted Therapies for Severe Asthma:Is There Any Place for "omics" Technology? [PDF]

, 2018
According to the current guidelines, severe asthma still represents a controversial topic in terms of definition and management. The introduction of novel biological therapies as a treatment option for severe asthmatic patients paved the way to a ...
Bertolini, Francesca, Caminati, Marco, Facciolongo, Nicola, Galeone, Carla, Menzella, Francesco, Ruggiero, Patrizia, Scelfo, Chiara   +6 more
core   +2 more sources

Predictors of response to omalizumab in chronic spontaneous urticaria [PDF]

, 2023
Zhirong Du, Yuxiang Zhi
openalex   +1 more source

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

Allergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau, Marcus Maurer, Adam Reich, Chia‐Yu Chu, Diana Deleanu, Gordon Sussman, Jorge Sanchez, Knut Brockow, Koremasa Hayama, Michihiro Hide, Mohamed Denguezli, Raisa Meshkova, Roberta F. J. Criado, Sarbjit Saini, Solange Valle, Eva Hua, Pengpeng Wang, Alis Burciu, Isabelle Indermuehle, Vineeth Varanasi, Yolandi Joubert, Thomas Severin, Manmath Patekar   +22 more
wiley   +1 more source

Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study

Allergology International, 2018
Background: Omalizumab, a humanized anti-IgE monoclonal antibody, proved efficacious and well tolerated in patients with chronic spontaneous urticaria (CSU) refractory to H1 antihistamines (H1AH) in the POLARIS study (NCT02329223), a randomized, double ...
Michihiro Hide, Atsuyuki Igarashi, Akiko Yagami, Yuko Chinuki, Naoko Inomata, Atsushi Fukunaga, Guenther Kaiser, Junyi Wang, Soichiro Matsushima, Steven Greenberg, Sam Khalil   +10 more
doaj   +1 more source

IgE autoantibodies and their association with the disease activity and phenotype in Bullous Pemphigoid: a systematic review [PDF]

, 2017
Bullous Pemphigoid (BP) is the most common autoimmune skin disease of blistering character. The underlying pathophysiological mechanism involves an immune attack, usually by IgG class autoantibodies, on the autoantigen BP 180/BPAg2, which is a type XVII ...
Fairclough, Lucy C., Hadjikyriacou Saniklidou, Ariadne, Tighe, Patrick J., Todd, Ian   +3 more
core   +2 more sources

Omalizumab prevents respiratory illnesses in non‐atopic chronic spontaneous urticaria patients: A prospective, parallel‐group, pilot pragmatic trial [PDF]

, 2023
George Ν. Konstantinou, Indrashis Podder, Dimitrios Karapiperis   +2 more
openalex   +1 more source

A Systematic Review and Meta‐Analysis on the Induction of Confirmed Eosinophilic Esophagitis as a Side Effect of Allergen Immunotherapy: An EAACI Task Force Report

Allergy, EarlyView.
ABSTRACT The European Academy of Allergy and Clinical Immunology (EAACI) established a Task Force to assess the existing data on the relationship between eosinophilic esophagitis (EoE) and allergen immunotherapy (AIT). This systematic review and meta‐analysis aimed to study the incidence of confirmed EoE, developing as a side effect of AIT to food or ...
Carlo Maria Rossi, Ingrid Terreehorst, Evaggelia Apostolidou, Martina Votto, Arzu Bakirtas, Antonella Cianferroni, George N. Konstantinou, Katerina Pantavou, Dario Antolin‐Amerigo, Enrico Heffler, Alberto Alvarez‐Perea, Montserrat Fernandez‐Rivas, Georgios K. Nikolopoulos, Oliver Pfaar, Constantinos Pitsios   +14 more
wiley   +1 more source